ACHC — Acadia Healthcare Company, Inc., the largest stand-alone behavioral healthcare provider in the United States — saw its stock rise 1.47% in Friday's trading session. Shares closed at $34.51, adding $0.50 from Thursday's closing price of $34.01. The move marked the latest leg in a sustained rally that has propelled the behavioral health operator's market capitalization to roughly $3.17 billion. Headquartered in Franklin, Tennessee, Acadia operates a network of approximately 275 facilities with roughly 12,400 beds across 40 states and Puerto Rico, providing inpatient psychiatric, substance abuse treatment, and outpatient behavioral health services.
A cluster of bullish analyst actions in July has been the primary catalyst behind ACHC's extraordinary run. On July 14, KeyBanc raised its price target to $40 from $30, maintaining an Overweight rating, while TD Cowen lifted its target to $36 from $30 with a Buy rating. Earlier in the month, UBS boosted its target to $39 from $31, and Guggenheim raised its target to $38 from $31. These revisions collectively signal Wall Street's growing conviction that Acadia's turnaround — anchored by returning CEO leadership, bed-capacity expansion, and improved earnings visibility — is gaining real traction. The stock has now blown past the average analyst price target of approximately $32, suggesting the market is pricing in further operational improvements ahead of the company's Q2 report.
Acadia Healthcare is scheduled to release its second-quarter 2026 results after the market closes on Tuesday, July 28, with a conference call set for Wednesday, July 29. Analysts are looking for earnings of approximately $0.33 per share on revenue near $848 million, while the company's own guidance calls for EPS in the $0.30–$0.40 range. The company beat expectations handily in Q1, delivering $0.37 per share versus the $0.28 consensus on revenue of $828.8 million — a 7.6% year-over-year increase. That beat, combined with raised full-year guidance for adjusted EBITDA and EPS, set the stage for the current rally. With the earnings event now just one trading day away, positioning flows and anticipation of another potential beat have contributed to Friday's gains.
Since the start of 2026, ACHC has undergone a dramatic transformation. The stock entered the year at $14.19 and has surged roughly 143% year-to-date, driven by a combination of new management, cost discipline, and improving facility-level performance. The return of former CEO leadership, the appointment of David Duckworth as Interim CFO, and a strategic focus on boosting underperforming assets have restored investor confidence. Institutional investors have taken note: Principal Financial Group increased its stake by 27.4% in the first quarter, while other large holders — including Wellington Management, Goldman Sachs, and Jefferies Financial Group — have materially expanded their positions. The stock's addition to the Russell 2000 Index after being dropped from the Russell 1000 has also broadened its institutional ownership base.
Friday's session saw roughly 2.3 million shares change hands, modestly below the three-month average volume of approximately 3.1 million. The stock traded in a range of $34.30 to $35.29, briefly testing but not surpassing the 52-week high of $35.83 set earlier in the week. The broader healthcare provider sector has been relatively steady, with peers such as THC and HCA posting solid Q2 results that buoyed sentiment across the group. Acadia's rally has far outpaced both the healthcare sector and the broader S&P 500, reflecting company-specific catalysts rather than a simple sector tailwind. Notably, short interest remains exceptionally elevated at roughly 36.6% of the float — approximately 21.8 million shares — which has amplified upside moves as short sellers face mounting pressure during the stock's relentless ascent.
The immediate focus for ACHC is Tuesday's Q2 earnings release. Beyond the headline numbers, investors will scrutinize same-facility volume trends, bed-ramp progress at newer facilities, margin trajectories, and updated full-year guidance. Key risks include the company's elevated debt load of roughly $2.69 billion, lingering legal overhangs including a $105 million jury verdict against a subsidiary, and the possibility that the rapid share-price appreciation has already priced in optimistic assumptions about the turnaround. On the bullish side, sustained demand for behavioral health services, expanding insurance coverage, and operational improvements under new leadership could extend the rally further. With the stock having more than tripled from its January lows, the Q2 report represents a critical test of whether the fundamentals can justify the extraordinary re-rating.
For traders seeking data-driven strategies in volatile markets like the one ACHC is navigating, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to adapt to evolving conditions. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the strongest real-time performance under current market dynamics are featured in this actively maintained section. Bots span a range of strategies, timeframes, and traded symbols, allowing users to identify approaches aligned with their own risk tolerance and market outlook. Explore the Trending AI Robots page to discover which automated strategies are currently outperforming.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsThe 10-day RSI Oscillator for ACHC moved out of overbought territory on July 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 19 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACHC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ACHC broke above its upper Bollinger Band on July 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on June 25, 2026. You may want to consider a long position or call options on ACHC as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
ACHC moved above its 50-day moving average on June 25, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ACHC crossed bullishly above the 50-day moving average on June 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ACHC advanced for three days, in of 294 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 175 cases where ACHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ACHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.621) is normal, around the industry mean (229.510). P/E Ratio (20.207) is within average values for comparable stocks, (124.449). ACHC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.993). ACHC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (0.926) is also within normal values, averaging (2.636).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACHC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
an operator of a network of behavioral health centers
Industry HospitalNursingManagement